<DOC>
	<DOCNO>NCT01872026</DOCNO>
	<brief_summary>This study ass safety , tolerability , plasma concentration pharmacodynamics ASP7991 oral administration patient chronic kidney disease undergoing hemodialysis .</brief_summary>
	<brief_title>Examination Plasma Concentrations Safety Chronic Kidney Disease Patients Undergoing Hemodialysis</brief_title>
	<detailed_description>To examine pharmacokinetics , pharmacodynamics safety patient chronic kidney disease undergoing hemodialysis . - To assess pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety effect hemodialysis PK single oral administration ASP7991 Part 1 . - To assess safety , PK PD repeat oral administration ASP7991 part 2 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients stable chronic maintenance dialysis receive hemodialysis therapy 3 times/week 12 week ( 84 day ) also schedule undergo regimen 3 times/week hemodialysis study period Patients secondary hyperparathyroidism ; 1 . Receiving Active vitamin D Cinacalcet hydrochloride 2 . OR iPTH value ≥ 180 pg/mL screen case patient receive medication secondary hyperparathyroidism . Corrected serum Ca screening：≥ 8.4 mg/dL No change item least 7 day screen plan change something item trial . 1 . Dose type Active Vitamin D , Calcitonin preparation , Phosphate binder . 2 . Ca concentration dialysate , membrane area dialyzer dialysis time week ( possible change within ±10 % ) Patients underwent parathyroid intervention within 24 week prior inform consent Patients primary hyperparathyroidism Having history gastric/intestinal resection consider influential absorption drug gastrointestinal tract Patients uncontrolled hypertension ( systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 120 mmHg show previous three point initiation dialysis include screen assessment ) Complicated severe heart disorder [ congestive cardiac failure ( NYHA classification III high ) , wide range old myocardial infarction ] , history hospitalization cerebrovascular disease heart disorder within 12 week ( 84 day ) obtain informed consent . Concurrent serious hepatic disease ( acute active chronic hepatitis , hepatic cirrhosis ) History malignant tumor History serious drug allergy include anaphylactic shock Potentially childbearing , lactating , comply instruct contraceptive measure Patients involve assessment clinical trial within 12 week ( 84 day ) prior inform consent Patients employee sponsor , CRO , SMO , sit relate study . Patients judge ineligible participate study investigator / sub investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Plasma concentration</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>ASP7991</keyword>
</DOC>